

**Table ST1.** Anti-SARS-CoV-2 IgG antibody seroprevalence, Greece, September 2020

September		Positive/ sample size	S1: Crude prevalence		S2: Age, sex and population-adjusted prevalence		S3: S2 + adjustment for sensitivity and specificity		S4: S3 + NPHO data	
		n/N	Prevalence (%)	95% CI	Prevalence (%)	95% CI	Prevalence (%)	95% CI	Prevalence (%)	95% CI
<b>Total</b>		59/7789	0,76	0.56–0.95	1,11	0.75-1.48	0,97	0.53-1.41	1,15	0.71-1.59
<b>Age group (years)</b>	0–29	13/1935	0,67	0.31-1.04	1,06	0.38-1.75	0,91	0.09-1.73	1,06	0.24-1.88
	30–49	20/2186	0,91	0.52 -1.31	1,1	0.42-1.77	0,95	0.14-1.76	1,16	0.35-1.97
	50–69	12/2121	0,57	0.25-0.88	0,84	0.21-1.47	0,65	0.00-1.40	0,83	0.18-1.58
	≥ 70	14/1547	0,9	0.43-1.38	1,69	0.48-2.90	1,67	0.22-3.11	1,78	0.33-3.22
<b>Sex</b>	Male	25/3043	0,82	0.50-1.14	1,05	0.49-1.61	0,89	0.22-1.57	1,09	0.41-1.76
	Female	35/4746	0,72	0.48-0.96	1,17	0.68-1.67	1,04	0.46-1.63	1,19	0.60-1.78
<b>‘N-1’ chi-squared test Difference between sex</b>			Difference = 0.10% p = 0.620		Difference = 0.12% p = 0.624		Difference = 0.15% p = 0.512		Difference = 0.10% p = 0.686	

**Table ST2. Anti-SARS-CoV-2 IgG antibody seroprevalence, Greece, October 2020**

October		Positive/ sample size	S1: Crude prevalence		S2: Age, sex and population-adjusted prevalence		S3: S2 + adjustment for sensitivity and specificity		S4: S3 + NPHO data	
		n/N	Prevalence (%)	95% CI	Prevalence (%)	95% CI	Prevalence (%)	95% CI	Prevalence (%)	
Total		78/8160	0.96	0.74-1.17	1.81	1.37-2.25	1.80	1.28–2.33	2.16	
Age group (years)	0–29	13/1630	0.80	0.37-1.23	2.87	1.76-3.98	3.07	1.74-4.40	3.40	
	30–49	30/2342	1.28	0.83-1.74	1.64	0.87-2.41	1.60	0.68-2.52	2.04	
	50–69	25/2292	1.09	0.67-1.52	1.59	0.76-2.41	1.54	0.56-2.52	1.91	
	≥ 70	10/1896	0.53	0.20-0.85	0.19	0-0.56	0.00	0.00-0.31	0.08	
Sex	Male	41/3401	1.21	0.84-1.57	2.92	2.08-3.75	3.12	2.13-4.12	3.51	
	Female	37/4759	0.78	0.53-1.03	0.75	0.38-1.13	0.54	0.09-1.00	0.86	
'N-1' chi-squared test Difference between sex			Difference = 0.43% p = 0.05		Difference = 2.17% p <0.001		Difference = 2.58% p <0.001		Difference = 2.65% p <0.001	

**Table ST3.** Anti-SARS-CoV-2 IgG antibody seroprevalence, Greece, November 2020

November		Positive/ sample size	S1: Crude prevalence		S2: Age, sex and population-adjusted prevalence		S3: S2 + adjustment for sensitivity and specificity		S4: S3 + NPHO data	
		n/N	Prevalence (%)	95% CI	Prevalence (%)	95% CI	Prevalence (%)	95% CI	Prevalence (%)	95% CI
<b>Total</b>		164/7069	2.32	1.97–2.67	3.06	2.40-3.72	3.30	2.51-4.09	4.28	3.49-5.07
<b>Age group (years)</b>	0–29	40/1456	2.75	1.91-3.59	2.37	1.06-3.68	2.47	0.90-4.04	3.25	1.68-4.82
	30–49	58/2108	2.75	2.05 -3.45	4.03	2.59-5.47	4.45	2.73-6.17	5.61	3.89-7.33
	50–69	44/2057	2.14	1.51-2.76	3.37	2.17-4.57	3.67	2.23-5.10	4.82	3.38-6.26
	≥ 70	22/1448	1.52	0.89-2.15	2.11	0.73-3.48	2.16	0.52-3.80	2.95	1.31-4.59
<b>Sex</b>	Male	78/2975	2.62	2.05-3.20	3.62	2.50-4.73	3.96	2.63-5.30	5.02	3.69-6.35
	Female	86/4094	2.10	1.66-2.54	2.52	1.73-3.31	2.65	1.70-3.60	3.59	2.64-4.54
<b>‘N-1’ chi-squared test Difference between sex</b>			Difference = 0.52% p = 0.152		Difference = 1.10% p = 0.007		Difference = 1.31% p = 0.002		Difference = 1.43% p = 0.003	

**Table ST4.** Anti-SARS-CoV-2 IgG antibody seroprevalence, Greece, December 2020

December		Positive/ sample size	S1: Crude prevalence		S2: Age, sex and population-adjusted prevalence		S3: S2 + adjustment for sensitivity and specificity		S4: S3 + NPHO data	
		n/N	Prevalence (%)	95% CI	Prevalence (%)	95% CI	Prevalence (%)	95% CI	Prevalence (%)	95% CI
Total		321/6231	5.15	4.60-5.70	7.91	6.70-9.13	9.09	7.64-10.55	10.40	8.95-11.85
Age group (years)	0–29	79/1336	5.91	4.65-7.18	10.09	7.46-12.73	11.70	8.56-14.85	12.67	9.52-15.81
	30–49	108/1847	5.85	4.78 -6.92	8.05	5.76-10.34	9.26	6.52-12.00	10.77	8.03-13.50
	50–69	98/1729	5.67	4.58-6.76	7.11	4.93-9.30	8.14	5.54-10.75	9.72	7.11-12.32
	≥ 70	36/1319	2.73	1.85-3.61	4.13	1.74-6.51	4.57	1.72-7.42	5.75	2.90-8.61
Sex	Male	130/2671	4.87	4.05-5.68	7.56	5.65-9.46	8.67	6.39-10.94	10.05	7.78-12.33
	Female	191/3560	5.37	4.62-6.11	8.24	6.64-9.85	9.49	7.58-11.41	10.76	8.85-12.68
'N-1' chi-squared test Difference between sex			Difference = 0.50% p = 0.377		Difference = 0.68% p = 0.326		Difference = 0.82% p = 0.226		Difference = 0.71% p = 0.365	

**Table ST5: Infection Fatality rates(deaths per 1,000 infections) for each month calculated by using different estimations of seroprevelnce (S1,S2,S3,S4)**

	s1			s2			S3			S4		
	IFR	LOWER LIMIT	UPPER LIMIT	IFR	LOWER LIMIT	UPPER LIMIT	IFR	LOWER LIMIT	UPPER LIMIT	IFR	LOWER LIMIT	UPPER LIMIT
<b>APRIL</b>	3,10	2,13	5,65	2,65	1,86	4,48	5,65	2,71	-	5,20	2,60	65,00
<b>MAY</b>	2,75	2,32	4,60	2,11	1,65	4,47	4,15	2,15	45,59	3,68	2,03	20,46
<b>JUNE</b>	2,78	2,23	4,71	2,22	1,62	5,37	6,46	2,67	51,28	4,67	2,14	25,61
<b>JULY</b>	2,18	1,74	3,56	1,94	1,41	4,22	5,31	2,45	54,13	3,85	1,86	24,88
<b>AUGUST</b>	2,39	1,73	4,57	2,13	1,50	4,71	5,51	2,81	71,23	3,75	1,88	20,94
<b>SEPTEMBER</b>	2,57	2,03	3,94	1,96	1,46	4,34	3,16	2,05	6,55	2,36	1,53	4,66
<b>OCTOBER</b>	3,16	2,54	4,56	2,01	1,57	3,14	2,75	2,01	4,23	2,00	1,37	3,02
<b>NOVEMBER</b>	6,54	5,53	8,33	5,07	4,03	7,32	5,91	4,58	8,25	4,20	3,32	5,60
<b>DECEMBER</b>	6,38	5,70	7,39	4,45	3,80	5,55	4,51	3,82	5,49	3,67	3,13	4,40